Sen. Tina Smith Sells Off Shares of Insulet Corporation (NASDAQ:PODD)

Senator Tina Smith (Democratic-Minnesota) recently sold shares of Insulet Corporation (NASDAQ:PODD). In a filing disclosed on May 10th, the Senator disclosed that they had sold between $100,001 and $250,000 in Insulet stock on May 7th.

Senator Tina Smith also recently made the following trade(s):

• Sold $100,001 – $250,000 in shares of DexCom (NASDAQ:DXCM) on 5/7/2026.
• Sold $100,001 – $250,000 in shares of DexCom (NASDAQ:DXCM) on 4/29/2026.
• Sold $100,001 – $250,000 in shares of Insulet (NASDAQ:PODD) on 4/29/2026.
• Sold $50,001 – $100,000 in shares of 3M (NYSE:MMM) on 3/31/2026.
• Sold $100,001 – $250,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 3/31/2026.

Insulet Stock Up 2.7%

PODD traded up $4.17 during midday trading on Tuesday, reaching $158.34. The company’s stock had a trading volume of 191,527 shares, compared to its average volume of 1,102,946. Insulet Corporation has a 1 year low of $148.30 and a 1 year high of $354.88. The stock’s 50-day moving average is $207.40 and its 200-day moving average is $261.40. The firm has a market capitalization of $10.97 billion, a price-to-earnings ratio of 36.75, a PEG ratio of 1.25 and a beta of 1.20. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $761.70 million during the quarter, compared to analyst estimates of $729.89 million. During the same quarter last year, the company earned $1.02 EPS. The firm’s revenue for the quarter was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, research analysts expect that Insulet Corporation will post 6.43 EPS for the current year.

Insider Activity at Insulet

In other Insulet news, Director Michael R. Minogue acquired 2,030 shares of the stock in a transaction dated Wednesday, February 25th. The shares were purchased at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the purchase, the director directly owned 17,483 shares of the company’s stock, valued at approximately $4,304,839.09. This trade represents a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 0.36% of the stock is owned by insiders.

Institutional Investors Weigh In On Insulet

A number of large investors have recently added to or reduced their stakes in PODD. NewEdge Advisors LLC boosted its stake in shares of Insulet by 44.8% in the 1st quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock worth $54,000 after buying an additional 64 shares during the last quarter. Cresset Asset Management LLC lifted its holdings in Insulet by 7.3% in the second quarter. Cresset Asset Management LLC now owns 2,587 shares of the medical instruments supplier’s stock valued at $813,000 after acquiring an additional 177 shares during the period. Cerity Partners LLC lifted its holdings in Insulet by 68.7% in the second quarter. Cerity Partners LLC now owns 17,262 shares of the medical instruments supplier’s stock valued at $5,423,000 after acquiring an additional 7,030 shares during the period. Sei Investments Co. boosted its position in Insulet by 27.4% in the second quarter. Sei Investments Co. now owns 137,643 shares of the medical instruments supplier’s stock worth $43,245,000 after purchasing an additional 29,584 shares during the last quarter. Finally, Treasurer of the State of North Carolina grew its stake in shares of Insulet by 2.5% during the 2nd quarter. Treasurer of the State of North Carolina now owns 32,752 shares of the medical instruments supplier’s stock valued at $10,290,000 after purchasing an additional 791 shares during the period.

Analyst Upgrades and Downgrades

Several brokerages recently commented on PODD. JPMorgan Chase & Co. cut their price objective on shares of Insulet from $340.00 to $275.00 and set an “overweight” rating on the stock in a research report on Thursday, May 7th. Raymond James Financial reduced their price target on shares of Insulet from $355.00 to $263.00 in a research report on Thursday, May 7th. Barclays lowered their price objective on Insulet from $286.00 to $198.00 and set an “underweight” rating on the stock in a research report on Thursday. Piper Sandler reduced their target price on Insulet from $360.00 to $210.00 in a report on Wednesday, May 6th. Finally, BTIG Research decreased their price target on Insulet from $320.00 to $260.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Nineteen research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $257.09.

About Senator Smith

Tina Smith (Democratic Party) is a member of the U.S. Senate from Minnesota. She assumed office on January 3, 2018. Her current term ends on January 3, 2027. Smith (Democratic Party) ran for re-election to the U.S. Senate to represent Minnesota. She won in the general election on November 3, 2020. Smith succeeded former Senator Al Franken (D). She assumed office on January 3, 2018. Smith won a full term in the special general election for the position on November 6, 2018. She defeated Karin Housley (R), Sarah Wellington (Legal Marijuana Now Party), and Jerry Trooien (Unaffiliated) to win the seat. She advanced to the general election after defeating five challengers in the special Democratic primary election on August 14, 2018. Smith previously served as the 48th lieutenant governor of Minnesota. She was elected to the position on a joint ticket with incumbent Governor Mark Dayton on November 4, 2014, and was sworn into office on January 5, 2015.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.